News

CAARE is happy to announce the opening of our CafePress store.

In a remarkable sign that support for animal research is declining, the world renowned Wellcome Sanger Institute in the UK recently announced the upcoming closure of its animal research facility.

At the heart of the wave of new technologies to replace animals in research are the biotech companies utilizing modern scientific methods that are fundamentally human, and not derived from animals.

CAARE recently connected with Dr. Jo Varshney, CEO and founder of VeriSIM Life. She established her company to solve the critical bottleneck in getting life-saving therapeutics from development to patients, a problem that is largely due to poor translatability from animal tests.

Amyotrophic Lateral Sclerosis (ALS) is a tragic, progressive, and fatal disease that causes nerve cells to degenerate, resulting in the gradual loss of muscle control. Increasing weakness eventually disrupts the body’s ability to move, swallow, and even breathe.

Despite the use of innumerable animals in cardiac experiments, cardiotoxicity – damage to the heart – remains the key reason drugs fail in clinical trials.

A growing number of scientists and biotech firms are working to change this by developing lab-grown, miniature beating human hearts. One such company, Novoheart, is pioneering an array of next-generation human heart tissue prototypes.

In November 2018, the Food and Drug Administration (FDA) released a statement claiming efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain animal drug trials.

Cystic fibrosis (CF) is a debilitating genetic disease caused by a mutation that disables essential proteins, resulting in thick mucus forming in the lungs, pancreas, and other organs. For patients, this results in a lifetime difficulty breathing and digestive problems. Tragically, the condition often limits the patient to a 40- or 50-year lifespan.

It’s a disturbing fact that in the U.S. alone, an estimated one million animals are used each year for the development and safety testing of medical devices, a growing multi-billion industry. Yet, an overwhelming 92% of tests that prove safe in animals fail in subsequent human clinical trials.

Mark M. Davis, PhD, has devoted his career to understanding the immune system and its link to disease. Now this esteemed Professor of Microbiology and Immunology at Stanford University School of Medicine is issuing a bold call for human immunology research that focuses on studying human patients, as opposed to artificially induced diseases in animals.

CAARE is building a movement to change the conversation about animal experiments, from a “necessary evil” to an outdated, inhumane and irrelevant method that doesn’t efficiently advance human medicine.

We consistently research and distribute information on the many ways in which biomedical research can be carried out effectively without animals. CAARE also speaks up for animals in laboratories through campaigns that highlight how their suffering is totally unwarranted.